|
|||||
|
|
Risk‐adjusted relationship between voriconazole utilization and non‐melanoma skin cancer among lung and heart/lung transplant patients |
|
| Authors: | JM McLaughlin O Equils KT Somerville JA Aram HT Schlamm VL Welch J Mardekian RG Barbers |
| Institution: | 1. Pfizer, Inc., , New York, New York, USA;2. Adult Asthma and Allergy Center, Lung Transplantation Program, Keck School of Medicine, University of Southern California, , Los Angeles, California, USA |
| Abstract: | |
| Keywords: | voriconazole non‐melanoma skin cancer confounding statistical adjustment risk adjustment lung transplant heart/lung transplant immunosuppression |